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Abstract Ellipticine is an anticancer agent that forms cova-
lent DNA adducts after enzymatic activation by cytochrome
P450 (CYP) enzymes, mainly by CYP3A4. This process is
one of the most important ellipticine DNA-damaging mech-
anisms for its antitumor action. Here, we investigated the
efficiencies of human hepatic microsomes and human
recombinant CYP3A4 expressed with its reductase,
NADPH:CYP oxidoreductase (POR), NADH:cytochrome b5
reductase and/or cytochrome b5 in Supersomes
TM to oxidize
this drug.Wealso evaluated the effectiveness of coenzymesof
two of the microsomal reductases, NADPH as a coenzyme of
POR, and NADH as a coenzyme of NADH:cytochrome b5
reductase, to mediate ellipticine oxidation in these enzyme
systems. Using HPLC analysis we detected up to five ellip-
ticine metabolites, which were formed by human hepatic
microsomes and human CYP3A4 in the presence of NADPH
or NADH. Among ellipticine metabolites, 9-hydroxy-,
12-hydroxy-, and 13-hydroxyellipticine were formed by
hepatic microsomes as the major metabolites, while 7-hy-
droxyellipticine and the ellipticine N2-oxide were the minor
ones. HumanCYP3A4 in SupersomesTMgenerated only three
metabolic products, 9-hydroxy-, 12-hydroxy-, and 13-hy-
droxyellipticine. Using the 32P-postlabeling method two
ellipticine-derived DNA adducts were generated by micro-
somes and the CYP3A4-Supersome system, both in the
presence of NADPH andNADH. These adducts were derived
from the reaction of 13-hydroxy- and 12-hydroxyellipticine
with deoxyguanosine in DNA. In the presence of NADPH or
NADH, cytochrome b5 stimulated the CYP3A4-mediated
oxidation of ellipticine, but the stimulation effect differed for
individual ellipticine metabolites. This heme protein also
stimulated the formation of both ellipticine-DNA adducts.
The results demonstrate that cytochromeb5 plays a dual role in
the CYP3A4-catalyzed oxidation of ellipticine: (1) cyto-
chrome b5 mediates CYP3A4 catalytic activities by donating
the first and second electron to this enzyme in its catalytic
cycle, indicating that NADH:cytochrome b5 reductase can
substituteNADPH-dependent POR in this enzymatic reaction
and (2) cytochrome b5 can act as an allosteric modifier of the
CYP3A4 oxygenase.
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Introduction
Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole, see
Fig. 1) and its derivatives are efficient anticancer com-
pounds that function through multiple mechanisms
participating in cell cycle arrest and initiation of apoptosis
(for a summary see [1–8]). The predominant mechanisms
of ellipticine’s biological effects were proposed to be
intercalation into DNA [1, 6, 9] and the inhibition of
topoisomerase II [1, 4, 6–8]. Further, we have shown that
this antitumor agent forms covalent DNA adducts after
enzymatic activation with cytochromes P450 (CYP) and
peroxidases [2, 4, 7, 8, 10–17], suggesting an additional
DNA-damaging effect of ellipticine. Of the CYP enzymes
investigated, human CYP3A4 is the most active enzyme
oxidizing ellipticine to 12-hydroxy- and 13-hydroxyellip-
ticine, reactive metabolites that dissociate to ellipticine-12-
ylium and ellipticine-13-ylium and bind to DNA (see
Fig. 1) [4, 5, 11, 12]. The CYP3A4 isoform also forms
other ellipticine metabolites, including 9-hydroxyellip-
ticine, which is a detoxification product, as well as
7-hydroxyellipticine and ellipticine N2-oxide as minor
metabolites (Fig. 1) [4, 5, 15, 16].
CYP enzymes, including CYP3A4, are components of
the monooxygenase system located in the membrane of the
endoplasmic reticulum (microsomes). This enzymatic
system also contains other enzymes such as NADPH:cy-
tochrome P450 oxidoreductase (POR) and cytochrome b5
accompanied with its reductase, NADH:cytochrome b5
reductase. The functions of this system are complex, but a
common feature is that, to perform the mono-oxygenation
reaction with molecular oxygen and all CYP enzymes
involved in the metabolism of xenobiotics receive electrons
from POR [18, 19].
The second electron needed for the reduction of CYP in
the monooxygenase reaction cycle may also be provided
by cytochrome b5 in the presence of POR or NADH:cy-
tochrome b5 reductase, but cytochrome b5 also plays
additional roles in the monooxygenase system
[15, 17, 20–24]. It was demonstrated that a second elec-
tron donor, cytochrome b5, could also modulate (stimulate
and/or inhibit) the activity of several CYPs [21, 25], both
in vitro [26–32] and in vivo [19, 24, 33–35]. Cytochrome
b5 has been reported to stimulate the oxidation of a variety
of CYP3A4 substrates, including ellipticine [15–17, 19,
26, 29, 36–38]. Interestingly, in the case of ellipticine,
cytochrome b5, when reconstituted with CYP3A4 and
POR, alters the ratio of ellipticine metabolites formed by
this CYP. Under these conditions, the amounts of the
detoxification metabolites (7-hydroxyellipticine and
9-hydroxyellipticine) were not changed with added cyto-
chrome b5, whereas oxidation of ellipticine to
12-hydroxyellipticine, 13-hydroxyellipticine, and ellip-
ticine N2-oxide, the metabolites responsible for the
formation of covalent DNA adducts [4, 5, 11–13],
increased considerably [15]. Consequently, this led to an
increase in the generation of ellipticine-derived DNA
adducts. Hence, cytochrome b5 seems to play a key role in
the CYP3A4-mediated DNA-damage caused by these
ellipticine metabolites [15, 16]. CYP3A4-mediated oxi-
dation of ellipticine was significantly changed only by
holo-cytochrome b5 containing heme, while neither apo-
cytochrome b5 without heme or Mn-cytochrome b5 had
such an effect [15].
Results found by Guengerich and his coworkers [26, 28]
demonstrated that cytochrome b5 added to recombinant
CYP3A4 reconstituted with POR enhanced CYP3A4
marker activity, testosterone 6-b-hydroxylation. They also
showed that this heme protein with NADH:cytochrome b5
reductase and NADH might even substitute the POR/
NADPH system in the CYP3A4 catalysis of this marker
reaction. Recently, we have found that the NADH:cy-
tochrome b5 reductase/cytochrome b5/NADH system can
also substitute the POR/NADPH system and act as an
electron donor to another CYP enzyme, CYP1A1, for the
oxidation of benzo[a]pyrene (BaP). This NADH-dependent
system can, therefore, function as a sole electron donor for
both reduction steps in the reaction cycles of CYP1A1
[39, 40] and CYP3A4 [26, 28]. Here, we investigated in
detail, whether the NADH:cytochrome b5 reductase/cy-
tochrome b5/NADH system can also be the sole electron
donor in the CYP3A4-catalyzed oxidation of ellipticine,
Another aim of this work was to shed more light on the
further functions of cytochrome b5 in this CYP3A4-medi-
ated reaction.
Results and discussion
Oxidation of ellipticine by human hepatic
microsomes and human CYP3A4 expressed
in SupersomesTM in the presence of NADPH
and NADH
In the last decade, we have studied in detail the CYP-
mediated oxidation of ellipticine using the monooxygenase
systems of several species founding that up to five oxidized
metabolites are formed [3–5, 8, 11, 15–17, 40–42]. Since
reactions of CYPs use molecular oxygen, electrons are
essential for this process. In addition to the classical
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reductase POR with its cofactor NADPH, cytochrome b5
plus NADH:cytochrome b5 reductase has come into focus,
and, therefore, its role in ellipticine oxidation was the aim
of this study. Three enzymatic systems were utilized for
such a study: (i) human hepatic microsomes, (ii) micro-
somes of baculovirus-infected insect cells (SupersomesTM)
Fig. 1 Scheme of ellipticine metabolism by CYPs and peroxidases
showing the identified metabolites and those proposed to form DNA
adducts. The compounds shown in brackets were not detected under
the experimental conditions and/or not structurally characterized. The
CYP enzymes predominantly oxidizing ellipticine shown in the
figure were identified in this work and/or in previous studies [11, 16]
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containing over-expressed amounts of human recombinant
CYP3A4 and POR, as well as the basal levels of
NADH:cytochrome b5 reductase and cytochrome b5, and
(iii) the analogous SupersomesTM, but also containing
over-expressed cytochrome b5, at a molar ratio of CYP3A4
to cytochrome b5 of 1:5. NADPH and NADH, cofactors of
the two microsomal reductases POR and NADH:cy-
tochrome b5 reductase, respectively, were utilized as
electron donors for CYP-mediated ellipticine oxidation.
The ellipticine metabolite profile formed by the used
enzymatic systems was determined by HPLC analysis and
ellipticine metabolites were identified by NMR and/or
mass spectrometry as described previously [11].
As shown in our previous studies [11, 16], in the pres-
ence of NADPH five ellipticine metabolites were formed in
human hepatic microsomes. They were structurally char-
acterized previously [11] to be 9-hydroxy-, 12-hydroxy-,
13-hydroxy-, and 7-hydroxyellipticine, in addition to N2-
oxide of ellipticine. Here, we show that three of these
metabolites are also formed in human hepatic microsomes
in the presence of NADH instead of NADPH (Fig. 2). As
with NADPH, 9-hydroxyellipticine and 13-hydroxyellip-
ticine were produced as the major metabolic products,
while 12-hydroxyellipticine was the minor one. 7-Hy-
droxyellipticine and ellipticine N2-oxide were not
detectable in the presence of NADH (Fig. 2). In the pres-
ence of NADH, the amounts of ellipticine metabolites were
up to five-times lower than in the presence of NADPH.
Negligible amounts or no ellipticine metabolites (7-hy-
droxyellipticine and ellipticine N2-oxide) were found when
NADPH or NADH was omitted from the incubation mix-
tures containing human hepatic microsomes (Fig. 2).
These results demonstrated that not only NADPH, but
also NADH acts as an electron donor for the reduction of
CYPs during ellipticine oxidation in human liver micro-
somes. These results also suggested that NADH can even
serve as an exclusive electron donor for CYP in its catalytic
cycle independent of NADPH and POR. This suggestion
was confirmed by the finding that NADH does not function
as a coenzyme of POR when cytochrome c is used as a
substrate [39, 40].
To evaluate the suitability of the CYP3A4-Super-
somesTM systems [see systems (ii) and (iii)] for our
experiments, we first tested whether they are functionally
active by testing the CYP3A4 marker activity, testosterone
6-b-hydroxylation. Our results showed that the Supersomal
CYP3A4 systems are capable of catalyzing this marker
reaction, both in the presence of NADPH and NADH, and
cytochrome b5 stimulated this reaction enormously
(Fig. 3). Based on these findings, we could argue that the
Supersomal CYP3A4 systems were suitable for our further
enzymatic studies, where ellipticine was analyzed to be a
CYP3A4 substrate. Our results with these CYP3A4
systems are fully in accordance with the studies by
Guengerich and his coworkers [26, 28], where they used
human recombinant CYP3A4 reconstituted either with
POR plus NADPH or NADH:cytochrome b5 reductase with
NADH in the presence of cytochrome b5 in liposomes.
Human recombinant CYP3A4 expressed in the Super-
somal enzymatic systems used here oxidized ellipticine
only to three metabolites; 9-hydroxy-, 12-hydroxy-, and
13-hydroxyellipticine, again both in the presence of
NADPH and NADH (Fig. 4). The formation of 7-hydrox-
yellipticine and the N2-oxide of ellipticine was too low to
be accurately quantified. NADH was less effective than
NADPH as electron donor. In control incubations per-
formed without the addition of external NADPH or NADH
only low amounts of ellipticine metabolites were detected
(Fig. 4).
Next, we utilized system (iii) where cytochrome b5 was
over-expressed with CYP3A4 and POR at a molar ratio of
CYP3A4:cytochrome b5 of 1:5 already in the cells from
which CYP3A4-SupersomesTM (microsomes) were iso-
lated. In the presence of NADPH, 4-, 5-, and 3.2-fold
increased levels of 9-hydroxy-, 12-hydroxy-, and 13-hy-
droxyellipticine, respectively, were produced (Fig. 4).
These results demonstrated that cytochrome b5 might
function as a donor for the second electron transferred by
POR from NADPH, which is in line with our earlier studies
[15, 16]. In our previous work [15] a different procedure to
include cytochrome b5 into Supersomes
TM was utilized.
Cytochrome b5 was reconstituted in Supersomes
TM, over-
expressing POR with CYP3A4 in vitro (again in a molar
ratio of CYP3A4:cytochrome b5 of 1:5). In this system,
reconstitution with cytochrome b5 only increased the
Fig. 2 Amounts of ellipticine metabolites generated by human
hepatic microsomes in the presence of NADPH or NADH. Data
shown are mean peak areas relative to the internal standard
phenacetin ± SD (n = 3; analyses of three independent in vitro
incubations). ND not detected, DDDP\ 0.001 (Student’s t test),
significantly different from incubations in the presence of NADPH as
a cofactor. Control—incubations without added cofactors
M. Stiborova´ et al.
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formation of 12-hydroxy- and 13-hydroxyellipticine but
not that of 9-hydroxyellipticine [15]. This finding indicated
that this heme protein does not only influence the transfer
of electrons during the second reduction of CYP3A4, but
that cytochrome b5 can also induce changes in the con-
formation of the CYP3A4 protein, leading to an altered
profile of ellipticine metabolites [15]. Indeed, our previous
studies have indicated a high specificity of interaction of
CYP3A4 with holo-cytochrome b5 containing heme, which
is necessary not only for electron transfer but also for the
natural conformation of the cytochrome b5 and CYP3A4
proteins [15]. These results, and those found for the
interaction of cytochrome b5 with CYP1A1 [17], demon-
strate that the natural three-dimensional structure of the
cytochrome b5 protein dictates the optimal conformational
state of the CYP-cytochrome b5 complex. Further, the
presence of the protoporphyrin IX bonded-Fe ion as an
electron transfer agent is necessary for the observed effects.
Now, we can only speculate on the reasons for the dif-
ferent results found here and in our former studies [15].
One reason might be that the co-expression of the CYP3A4
and cytochrome b5 proteins from their cDNA into the
membrane of endoplasmic reticulum may produce protein
molecules in conformation states that are different from
those generated after the reconstitution of cytochrome b5
with CYP3A4 in SupersomesTM, thus leading to different
enzymatic activity of the monooxygenase system. How-
ever, this suggestion awaits further investigation.
In the presence of NADH, cytochrome b5 over-expressed
in CYP3A4-SupersomesTM also enhanced ellipticine oxida-
tion to individual metabolites, but to different degrees;
9-hydroxyelliptice by 11-fold, 12-hydroxyellipticine by 1.3-
fold, and 13-hydroxyellipticine by 6.5-fold, which led to the
formation of an altered pattern of ellipticine metabolites
compared to basal levels without over-expressed cytochrome
b5 (Fig. 4). This finding demonstrated that cytochrome b5
influences the CYP3A4 catalytic activity in at least two ways.
First, this heme protein canmediate CYP3A4 enzyme activity
even in the absence of the NADPH/POR system, by donating
both the first and second electron from NADH to CY3A4 in
the catalytic cycle. This again indicates that the NADH:cy-
tochrome b5 reductase as an NADH-dependent reductase can
substitute POR in this enzymatic reaction and that the NADH/
NADH:cytochrome b5/cytochrome b5 system might act as an
exclusive donor of electrons for this CYP3A4-mediated
ellipticine oxidation independent of NADPH and POR. Sec-
ond, cytochrome b5 can also induce changes in the
conformation of the CYP3A4 protein, resulting in changes in
profile of ellipticine metabolite formation.
Formation of ellipticine-derived-DNA adducts
by human hepatic microsomes and human CYP3A4
expressed in SupersomesTM in the presence
of NADPH and NADH
In further experiments, DNA adduct formation was ana-
lyzed in incubations with ellipticine and human hepatic
Fig. 3 Testosteron 6-b-hydroxylation catalyzed by CYP3A4-Super-
somesTM with and without cytochrome b5 (at a molar ratio of
CYP3A4:cytochrome b5 of 1:5) in the presence of NADPH or NADH.
Data shown are mean peak areas relative to the internal standard
phenacetin ± SD (n = 3; analyses of three independent in vitro
incubations). ND not detected. DDDP\ 0.001, DP\ 0.05 (Student’s
t test), significantly different from incubations in the presence of
NADPH as a cofactor; ***P\ 0.001 (Student’s t test), significantly
different from incubations without cytochrome b5
Fig. 4 Amounts of ellipticine metabolites generated by human
CYP3A4 in the presence of NADPH or NADH with or without
cytochrome b5 (at a molar ratio of CYP3A4:cytochrome b5 of 1:5).
Data shown are mean peak areas relative to the internal standard
phenacetin ± SD (n = 3; analyses of three independent in vitro
incubations). ND not detected. DDDP\ 0.001, DP\ 0.01 (Student’s
t test), significantly different from incubations in the presence of
NADPH as a cofactor; ***P\ 0.001 (Student’s t test), significantly
different from incubations without cytochrome b5. Control—incuba-
tions without added cofactors
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microsomes or human CYP3A4 in SupersomesTM in the
presence of DNA.
Two DNA adducts were detected by the 32P-postlabel-
ing method [2, 11–16] derived from ellipticine activated
with human hepatic microsomes or CYP3A4-Super-
somesTM (Fig. 5), both in the presence of NADPH and
NADH (Figs. 6, 7). One major adduct (assigned spot 1 in
Fig. 5a–d) was previously shown [11] to be generated by
the reaction of guanine in DNA with ellipticine-13-ylium
which is formed by the decomposition of 13-hydroxyel-
lipticine (Fig. 1). One minor adduct (assigned adduct spot
2 in Fig. 5a–c, e) was previously shown [12] to be gener-
ated by reaction of guanine in DNA with ellipticine-12-
ylium formed from 12-hydroxyellipticine (Fig. 1). These
two adducts were analogous to those formed in several
cancer cells in vitro [43–46] and in healthy [13, 14, 47]
(Fig. 5c) and tumor tissues in vivo [4].
The levels of ellipticine-derived adduct 1 (formed pre-
dominantly by CYP3A4) [11, 15, 16] generated in human
microsomes were 2.8-fold lower with NADH than with
NADPH as the cofactor (Fig. 6), which is in agreement
with a 2.6-fold lower efficiency of ellipticine oxidation to
13-hydroxyellipticine by human microsomes in the pres-
ence of NADH (Fig. 2). Control incubations carried out
without NADPH or NADH were essentially free of adduct
spot 1, but adduct spot 2 was always detected (Fig. 6),
indicating that adduct 2 might be also formed by autooxi-
dation as reported previously [2, 4].
With human recombinant CYP3A4 expressed in
SupersomesTM the adducts formed were the same as those
generated by human hepatic microsomes, both in the
presence of NADPH and NADH. But NADH as a coen-
zyme was again less efficient than NADPH (Fig. 7). When
NADPH or NADH was omitted from the incubation mix-
tures containing CYP3A4-SupersomesTM, only low
amounts of adduct spot 2 were detected (Fig. 7).
In accordance with an increase in ellipticine oxidation
catalyzed by CYP3A4-SupersomesTM with over-expressed
cytochrome b5, shown in Fig. 4, the presence of this heme
protein in the CYP3A4 system led to higher levels of
ellipticine-derived DNA adducts, both in the presence of
NADPH and NADH (Fig. 7).
Conclusions
The present study was aimed to advance our knowledge
regarding the role of cytochrome b5 in the reaction cycle of
CYP3A4 catalyzing the oxidation of the anticancer drug
ellipticine. Our results demonstrated that the function of
cytochrome b5 in this reaction is complex. We found that
oxidation of ellipticine by human CYP3A4 in the natural
microsomal system of human liver or in SupersomesTM,
where the reductases POR and NADH:cytochrome b5
reductase and cytochrome b5 are expressed, is enhanced by
cytochrome b5. Ellipticine oxidation does not only occur in
the presence of the coenzymes of POR, NADPH, but also
in the presence of NADH, which is the exclusive coenzyme
Fig. 5 Autoradiographic profile of 32P-labeled DNA adducts gener-
ated in calf thymus DNA by ellipticine after its activation with
CYP3A4 in the presence of NADPH without (a) and with cytochrome
b5 (CYP3A4:cytochrome b5 of 1:5) (b): of
32P-labeled digests of
DNA from the liver of a male rat treated with 40 mg ellipticine per kg
body weight (c) [47]: from calf thymus DNA reacted with
13-hydroxyellipticine (d) [11] or 12-hydroxyelipticine (e) [12].
Analyses were performed by the nuclease P1 version of the 32P-
postlabeling assay. Adduct spots 1–7 correspond to the ellipticine-
derived DNA adducts
Fig. 6 DNA adduct formation by ellipticine activated with human
hepatic microsomes in the presence of either NADPH or NADH.
Values represent the mean total RAL (relative adduct labeling) ± SD
(n = 3; analyses of three independent in vitro incubations).
DDDP\ 0.001 (Student’s t test), significantly different from incuba-
tions with NADPH. Control—incubations without added cofactors
M. Stiborova´ et al.
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of another microsomal reductase, NADH:cytochrome b5
reductase. These findings demonstrated that cytochrome b5
is included in the reduction of CYP3A4 catalyzed both by
the NADPH/POR system and a system consisting exclu-
sively of NADH, NADH:cytochrome b5 reductase and
cytochrome b5, and thus also without any participation of
NADPH and POR. Our data confirmed previous results
found for CYP3A4 [26, 28] and for CYP1A1 [39, 40] that
NADH:cytochrome b5 reductase/cytochrome b5/NADH
can replace NADPH/POR in the catalytic cycle of the CYP
reactions in the monooxygenase system [18, 19]. This is an
important finding, because substitution of the POR/
NADPH system by another reductase system might be
clinically relevant for compensation or the lack of defect in
POR in patients suffering from diseases caused by muta-
tions of the POR gene. For example for patients with
Antley-Bixler syndrome (OMIM 201750), a disorder
characterized by severe developmental abnormalities and
exhibiting considerable numbers of different haplotypes of
the POR gene [48, 49]. Investigation of this feature is,
therefore, a challenge for future studies.
Here, we showed that if NADPH is substituted by
NADH, ellipticine oxidation is catalyzed by experimental
CYP3A4 enzymatic systems. Such NADH-mediated
activity of the employed CYP3A4 systems was proven by
the formation of oxidized ellipticine metabolites as well as
by the generation of ellipticine-derived DNA adducts,
which were the same as in the system where NADPH was
used as electron donor.
The results of our present study as well as those reported
previously [15] indicated that cytochrome b5 can play a
dual role in the CYP3A4-mediated oxidation of ellipticine.
Specifically, as shown here, (i) it acts as a sole electron
donor to CYP3A4 during its reaction cycle and (ii) it can
also act as an allosteric modifier of CYP3A4 oxygenase
[15]. The finding that cytochrome b5 with its reductase,
NADH:cytochrome b5 reductase, functions as an exclusive
donor for both electrons in the first and second reduction
steps of the CYP3A4-catalyzed oxidation of ellipticine
opens the door for further research. It will be a challenge to
study the kinetics and structural features of this novel
phenomenon.
Experimental
Chemicals and CYP3A4 subcellular systems
Ellipticine, NADH (as disodium salt; purity *95%), and
NADPH (as tetrasodium salt;*98% purity) were obtained
from Sigma Chemical Co (St Louis, MO, USA). Testos-
terone and 6-b-hydroxytestosterone were purchased from
Merck (Darmstadt, Germany).
CYP3A4 subcellular systems
CYP3A4-SupersomesTM, microsomes isolated from insect
cells transfected with a baculovirus construct containing
cDNA of human CYP3A4 and POR that are, therefore,
over-expressed in these microsomes, were purchased from
the Gentest Corp. (Woburn, MI, USA). However, because
they are microsomes (particles of broken endoplasmic
reticulum), other enzymes (proteins) of the endoplasmic
reticulum membrane (i.e. NADH:cytochrome b5 reductase
and cytochrome b5) are also expressed at basal levels in
these SupersomesTM (Gentest Corp., Woburn, MI, USA).
We also utilized CYP3A4-SupersomesTM which also con-
tained over-expressed cytochrome b5, in a molar ratio of
CYP3A4 to cytochrome b5 of 1–5 (Gentest Corp., Woburn,
MI, USA). Pooled human hepatic microsomes were from
Gentest Corp. (Woburn, MI, USA).
Incubations to study the metabolism of ellipticine
Incubation mixtures used to study the ellipticine metabo-
lism by human hepatic microsomes or SupersomesTM
contained in a final volume of 0.5 cm3 100 mmol dm-3
potassium phosphate buffer (pH 7.4), 1 mmol dm-3
NADPH or NADH, 0.025 mmol dm-3 ellipticine (dis-
solved in 0.005 cm3 dimethyl sulfoxide, DMSO) and
Fig. 7 DNA adduct formation (RAL, relative adduct labelling) by
ellipticine activated with human CYP3A4 in the presence of either
NADPH or NADH and the effect of cytochrome b5 (cyt b5) (at a
molar ratio of CYP3A4:cytochrome b5 of 1:5) on this reaction. Values
represent mean total RAL (relative adduct labeling) ± SD (n = 3;
analyses of three independent in vitro incubations). DDDP\ 0.001
(Student’s t test), levels of ellipticine-derived DNA adducts signif-
icantly different from incubations with NADPH as a cofactor;
***P\ 0.001 (Student’s t test), levels of ellipticine-derived DNA
adducts significantly different from incubations without cytochrome
b5. Control—incubations without added cofactors
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0.5 mg protein of human hepatic microsomes or
100 nmol dm-3 human recombinant CYP3A4 in Super-
somesTM either with or without cytochrome b5. The same
amount of solvent (DMSO) was used in control incubations
without ellipticine. With this DMSO concentration (1%
final concentration), no inhibition of the NADPH-depen-
dent CYP-catalyzed oxidation of several substrates has
been found previously [10, 11, 15–17]. The reaction was
initiated by adding the NADPH or NADH. Negative con-
trols lacked either microsomes or SupersomesTM or
cofactors or ellipticine. After incubation (37 C, 20 min),
0.005 cm3 1 mmol dm-3 phenacetin in methanol was
added as an internal standard; ellipticine metabolism by
microsomes has been shown to be linear up to 30 min of
incubation [3, 11]. Ellipticine metabolites were extracted
twice with ethyl acetate (2 9 1 cm3), the solvent was
evaporated to dryness, residues were dissolved in
0.025 cm3 methanol and ellipticine metabolites were sep-
arated by HPLC as reported [3, 11, 15–17]. Ellipticine
metabolite peaks were analyzed by HPLC by comparison
with metabolite standards whose structures were deter-
mined previously by NMR and/or mass spectrometry
[11, 12].
Incubations to study 6-b-testosterone hydroxylation
by CYP3A4 in SupersomesTM
The incubation mixtures for measuring the testosterone
metabolism contained in a final volume of 0.5 cm3:
100 mmol dm-3 potassium phosphate buffer (pH 7.4),
50 lmol dm-3 testosterone (0.0025 cm3 of stock methanol
solution per incubation), 1 mmol dm-3 NADPH or
NADH, and 100 nmol dm-3 human recombinant CYP3A4
in SupersomesTM either with or without cytochrome b5.
The same amount of solvent (methanol) was used in con-
trol incubations without testosterone. The reaction was
initiated by adding the NADPH or NADH. Negative con-
trol reactions lacked either CYP3A4-SupersomesTM
systems, cofactors or testosterone. After incubation (for
15 min, at 37 C in a shaking incubator), 0.005 cm3
1 mmol dm-3 phenacetin in methanol was added as an
internal standard; testosterone oxidation was linear up to
30 min of incubation (data not shown). The reaction was
terminated by the addition of 0.1 cm3 of 1 mol dm-3
aqueous Na2CO3 containing 2 mol dm
-3 NaCl. The
metabolites were extracted with 2 9 1 cm3 of dichlor-
omethane and the extracts were evaporated to dryness. The
residues were dissolved in the mobile phase for HPLC (see
below). Testosterone and its metabolite 6-b-hydrox-
ytestosterone were separated on Nucleosil (C18) HPLC
column (4.6 9 25 mm, 5 lm, Macherey–Nagel, Ger-
many). The flow rates, mobile phases and detection
wavelength were 0.7 cm3 per min, 65:35 methanol/H2O (v/
v), and 254 nm, respectively [50, 51].
Determination of DNA adduct formation
by ellipticine by 32P-postlabeling
Incubation mixtures used to assess DNA adduct formation
by ellipticine contained 0.5 mg protein of human hepatic
microsomes or 100 nmol dm-3 human recombinant
CYP3A4 in SupersomesTM either with or without cyto-
chrome b5, 0.1 mmol dm
-3 ellipticine (dissolved in
0.0075 cm3 methanol), and 0.5 mg of calf thymus DNA in
a final volume of 0.75 cm3 as described previously
[2, 4, 15, 16]. The reaction was initiated by adding
0.1 mmol dm-3 ellipticine and incubations were carried
out at 37 C for 60 min. The ellipticine-derived DNA
adduct formation was shown to be linear up to 90 min
[2, 11, 15, 16]. Control incubations were carried out either
without human hepatic microsomes or CYP3A4 in Super-
somesTM without NADPH (or NADH), without DNA, or
without ellipticine. After the incubation, DNA was isolated
from the residual water phase by standard phenol/chloro-
form extraction. DNA adduct formation was analysed
using the nuclease P1 version of the 32P-postlabeling
technique [2, 11, 15, 16]. Resolution of the adducts by thin-
layer chromatography (TLC) using polyethylenimine-cel-
lulose plates (Macherey and Nagel, Du¨ren, Germany) was
carried out as described [2, 11, 15, 16]. DNA adduct levels
(RAL relative adduct labeling) were calculated as described
[52].
Statistical analyses
Statistical analyses were carried out with mean ± standard
deviations (from the original data) of at least three parallel
experiments with Student’s t test (UNISTAT Statistics
Software v6, Unistat Ltd., Highgate, London N6 5UQ,
UK). All P values were two-tailed and considered signifi-
cant at the 0.05 level.
Acknowledgements Supported by GACR (Grant 17-12816S) and
Charles University (Grant UNCE 204025/2012). Work at King’s
College London was also supported by Cancer Research UK (Grant
No. C313/A14329). Wellcome Trust (Grants 101126/Z/13/Z and
101126/B/13/Z) and Natural Environmental Research Council (Grant
NE/L006782/1).
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
M. Stiborova´ et al.
123
References
1. Auclair C (1987) Arch Biochem Biophys 259:1
2. Stiborova´ M, Bieler CA, Wiessler M, Frei E (2001) Biochem
Pharmacol 62:1675
3. Stiborova´ M, Borˇek-Dohalska´ L, Aimova´ D, Kotrbova´ V,
Kukacˇkova´ K, Janouchova´ K, Rupertova´ M, Rysˇlava´ H, Hudecˇek
J, Frei E (2006) Gen Physiol Biophys 25:245
4. Stiborova´ M, Rupertova´ M, Frei E (2011) Biochim Biophys Acta
1814:175
5. Stiborova´ M, Cˇerna´ V, Moserova´ M, Mrı´zova´ I, Arlt VM, Frei E
(2015) Int J Mol Sci 16:284
6. Garbett NC, Graves DE (2004) Curr Med Chem Anti-Cancer
Agents 4:149
7. Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, Burda
JV, Frei E, Stiborova M (2012) Pharmacol Ther 133:26
8. Stiborova M, Frei E (2014) Current Med Chem 21:575
9. Tmejova K, Krejcova L, Hynek D, Adam V, Babula P, Trnkova
L, Stiborova M, Eckschlager T, Kizek R (2014) Anti-Cancer Age
Med 14:331
10. Stiborova´ M, Stiborova´-Rupertova´ M, Borˇek-Dohalska´ L,
Wiessler M, Frei E (2003) Chem Res Toxicol 16:38
11. Stiborova M, Sejbal J, Borˇek-Dohalska´ L, Aimova´ D, Poljakova´
J, Forsterova´ K, Rupertova´ M, Wiesner J, Hudecˇek J, Wiessler M,
Frei E (2004) Cancer Res 64:8374
12. Stiborova M, Poljakova´ J, Rysˇlava´ H, Dracˇı´nsky´ M, Eckschlager
T, Frei E (2007) Int J Cancer 120:243
13. Stiborova M, Rupertova´ M, Aimova´ D, Rysˇlava´ H, Frei E (2007)
Toxicology 236:50
14. Stiborova M, Arlt VM, Henderson CJ, Wolf CR, Kotrbova V,
Moserova M, Hudecek J, Phillips DH, Frei E (2008) Toxicol
Appl Pharmacol 226:318
15. Stiborova M, Indra R, Moserova M, Cerna V, Rupertova M,
Martinek V, Eckschlager T, Kizek R, Frei E (2012) Chem Res
Toxicol 25:1075
16. Stiborova M, Poljakova J, Martı´nkova E, Ulrichova J, Simanek
V, Dvorak Z, Frei E (2012) Toxicology 302:233
17. Kotrbova V, Mrazova B, Moserova M, Martinek V, Hodek P,
Hudecek J, Frei E, Stiborova M (2011) Biochem Pharmacol
82:669
18. Pandey AV, Flu¨ck CE (2013) Pharmacol Ther 138:229
19. Henderson CJ, McLaughlin LA, Scheer N, Stanley LA, Wolf CR
(2015) Mol Pharmacol 87:733
20. Indra R, Moserova M, Sulc M, Frei E, Stiborova M (2013) Neuro
Endocrinol Lett 34(Suppl 2):55
21. Guengerich FP (2008) Chem Res Toxicol 21:70
22. Porter TD (2002) J Biochem Mol Toxicol 16:311
23. Schenkman JB, Jansson I (2003) Pharmacol Ther 97:139
24. McLaughin LA, Ronseaux S, Finn RD, Henderson CJ, Wolf CR
(2010) Mol Pharmacol 75:269
25. Baron J, Hildebrandt AG, Peterson JA, Estabrook RW (1973)
Drug Metab Dispos 1:129
26. Yamazaki H, Johnson WW, Ueng YF, Shimada T, Guengerich
FP (1996) J Biol Chem 271:27438
27. Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N,
Gillam EM, Guengerich FP, Shimada T, Yokoi T (1999) Drug
Metab Dispos 27:999
28. Yamazaki H, Shimada T, Martin MV, Guengerich FP (2001) J
Biol Chem 276:30885
29. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N,
Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M,
Yokoi T (2002) Protein Expr Purif 24:329
30. Lamb DC, Kaderbhai NN, Venkateswarlu K, Kelly DE, Kelly SL,
Kaderbhai MA (2001) Arch Biochem Biophys 395:78
31. Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate
T, Fujita KI, Kamataki T (2003) Biochem Pharmacol 66:2333
32. Akhtar MK, Kelly SL, Kaderbhai MA (2005) J Endocrinol
187:267
33. Finn RD, McLaughlin LA, Ronseaux S, Rosewell I, Houston JB,
Henderson CJ, Wolf CR (2008) J Biol Chem 283:31385
34. Henderson CJ, McLaughlin LA, Wolf CR (2013) Mol Pharmacol
83:1209
35. Henderson CJ, McLaughlin LA, Finn RD, Ronseaux S, Kape-
lyukh Y, Wolf CR (2014) Drug Metab Dispos 42:70
36. Gilep AA, Guryev OL, Usanov SA, Estabrook RW (2001) J Inorg
Biochem 87:237
37. Inui H, Maeda A, Ohkawa H (2007) Biochemistry 46:10213
38. Lee SJ, Goldstein JA (2012) Drug Metab Pharmacokinet 27:663
39. Stiborova´ M, Indra R, Moserova´ M, Sˇulc M, Hodek P, Frei E,
Schmeiser HH, Arlt V (2016) Monatsh Chem 147:847
40. Stiborova´ M, Indra R, Moserova´ M, Frei E, Schmeiser HH, Kopka
K, Phillips DH, Arlt VM (2016) Chem Res Toxicol 29:1325
41. Mrı´zova´ I, Moserova´ M, Milichovsky´ J, Sˇulc M, Kizek R,
Kuba´cˇkova´ K, Arlt VM, Stiborova´ M (2016) Monatsh Chem
147:881
42. Stiborova´ M, Moserova´ M, Mrı´zova´ I, Dracˇı´nska´ H, Martı´nek V,
Indra R, Frei E, Adam V, Kizek R, Schmeiser HH, Kuba´cˇkova´ K,
Arlt VM (2016) Monatsh Chem 147:897
43. Borek-Dohalska L, Frei E, Stiborova´ M (2004) Collect Czech
Chem Commun 69:603
44. Poljakova´ J, Frei E, Gomez JE, Aimova´ D, Eckschlager T,
Hrabeta J, Stiborova´ M (2007) Cancer Lett 252:270
45. Poljakova´ J, Eckschlager T, Hrabeta J, Hrebackova´ J, Smutny´ S,
Frei E, Martı´nek V, Kizek R, Stiborova´ M (2009) Biochem
Pharmacol 77:1466
46. Martinkova E, Dontenwill M, Frei E, Stiborova M (2009) Neuro
Endocrinol Lett 30(Suppl 1):60
47. Stiborova´ M, Breuer A, Aimova´ D, Stiborova´-Rupertova´ M,
Wiessler M, Frei E (2003) Int J Cancer 107:885
48. Antley R, Bixler D (1975) Birth Defects Orig Artic Ser 11:397
49. Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS,
Kranendonk M (2012) Drug Metab Dispos 40:754
50. Borek-Dohalska´ L, Hodek P, Sulc M, Stiborova´ M (2001) Chem
Biol Interact 138:85
51. Borek-Dohalska´ L, Stiborova´ M (2010) Collect Czech Chem
Commun 75:201
52. Schmeiser HH, Stiborova M, Arlt VM (2013) Methods Mol Biol
1044:389
Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during…
123
